Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:CGTX NASDAQ:IRD NASDAQ:KZR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.81-9.6%$3.48$1.78▼$8.56$100.93M0.98763,294 shs270,396 shsCGTXCognition Therapeutics$1.83-6.2%$1.77$0.22▼$3.83$134.55M1.193.28 million shs2.52 million shsIRDOpus Genetics$1.96-1.5%$1.41$0.65▼$2.16$117.42M0.11431,866 shs590,988 shsKZRKezar Life Sciences$4.22-4.1%$3.93$3.53▼$8.95$30.90M0.6247,650 shs20,060 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-9.59%-10.76%+45.32%+89.37%-36.04%CGTXCognition Therapeutics-6.15%+18.06%-27.09%+222.52%+357.50%IRDOpus Genetics-1.51%+4.26%+47.37%+73.45%+195,999,900.00%KZRKezar Life Sciences-4.09%+7.65%+5.50%-6.43%-51.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.81-9.6%$3.48$1.78▼$8.56$100.93M0.98763,294 shs270,396 shsCGTXCognition Therapeutics$1.83-6.2%$1.77$0.22▼$3.83$134.55M1.193.28 million shs2.52 million shsIRDOpus Genetics$1.96-1.5%$1.41$0.65▼$2.16$117.42M0.11431,866 shs590,988 shsKZRKezar Life Sciences$4.22-4.1%$3.93$3.53▼$8.95$30.90M0.6247,650 shs20,060 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-9.59%-10.76%+45.32%+89.37%-36.04%CGTXCognition Therapeutics-6.15%+18.06%-27.09%+222.52%+357.50%IRDOpus Genetics-1.51%+4.26%+47.37%+73.45%+195,999,900.00%KZRKezar Life Sciences-4.09%+7.65%+5.50%-6.43%-51.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.40Hold$19.75310.60% UpsideCGTXCognition Therapeutics 2.80Moderate Buy$2.8354.83% UpsideIRDOpus Genetics 2.50Moderate Buy$7.33274.15% UpsideKZRKezar Life Sciences 2.00Hold$9.00113.27% UpsideCurrent Analyst Ratings BreakdownLatest KZR, CGTX, ADVM, and IRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CGTXCognition TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025IRDOpus GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025KZRKezar Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (D-)9/27/2025CGTXCognition TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025IRDOpus GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025KZRKezar Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/23/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/13/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.008/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M100.91N/AN/A$3.40 per share1.41CGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/AIRDOpus Genetics$10.99M10.68N/AN/A$0.21 per share9.33KZRKezar Life Sciences$7M4.41N/AN/A$16.02 per share0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)CGTXCognition Therapeutics-$33.97M-$0.67N/AN/AN/AN/A-251.23%-130.75%11/12/2025 (Estimated)IRDOpus Genetics-$57.53M-$1.92N/AN/AN/A-377.89%-384.33%-148.90%11/11/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%11/11/2025 (Estimated)Latest KZR, CGTX, ADVM, and IRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/3/2025Q3 2025ADVMAdverum Biotechnologies-$1.80N/AN/AN/AN/AN/A8/13/2025Q2 2025IRDOpus Genetics-$0.25-$0.12+$0.13-$0.12$4.27 million$2.88 million8/13/2025Q2 2025KZRKezar Life Sciences-$2.15-$1.87+$0.28-$1.87N/AN/A8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/A8/7/2025Q2 2025CGTXCognition Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54CGTXCognition TherapeuticsN/A1.541.54IRDOpus Genetics0.061.901.90KZRKezar Life Sciences0.037.297.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%CGTXCognition Therapeutics43.35%IRDOpus Genetics14.97%KZRKezar Life Sciences67.90%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%CGTXCognition Therapeutics14.40%IRDOpus Genetics6.60%KZRKezar Life Sciences10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableCGTXCognition Therapeutics2073.52 million62.94 millionNot OptionableIRDOpus Genetics1459.91 million55.95 millionN/AKZRKezar Life Sciences607.32 million6.56 millionNot OptionableKZR, CGTX, ADVM, and IRD HeadlinesRecent News About These CompaniesAll You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to BuySeptember 17, 2025 | zacks.comKezar Life Sciences to Participate in Two Upcoming Investor ConferencesAugust 28, 2025 | businesswire.comWilliam Blair Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)August 15, 2025 | theglobeandmail.comKezar Narrows Loss 37 Percent in Q2August 13, 2025 | aol.comAKezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)August 13, 2025 | msn.comKezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | businesswire.comKezar sees hepatitis hold lifted, hints at resurrecting lupus programJuly 16, 2025 | fiercebiotech.comFFDA lifts partial hold on Kezar’s zetomipzomib trialJuly 16, 2025 | thepharmaletter.comTKezar Life Sciences Says FDA Lifts Clinical HoldJuly 16, 2025 | marketwatch.comKezar Life Sciences stock gains after FDA lifts partial clinical holdJuly 16, 2025 | uk.investing.comKezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune HepatitisJuly 15, 2025 | businesswire.comKezar Life Sciences Inc. Research & Ratings | KZR | Barron'sJuly 13, 2025 | barrons.comKZR | Kezar Life Sciences Inc. Stock Overview (U.S.: Nasdaq) - Barron'sJune 30, 2025 | barrons.comKezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?May 27, 2025 | zacks.comKezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | businesswire.comKezar toplines small Phase 2a dataset in autoimmune liver diseaseMarch 27, 2025 | endpts.comEKezar Life Sciences price target lowered to $7 from $9 at Wells FargoMarch 27, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)March 26, 2025 | markets.businessinsider.comKezar Life Sciences reports topline results from PORTOLA trialMarch 26, 2025 | markets.businessinsider.comKezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)March 25, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKZR, CGTX, ADVM, and IRD Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$4.81 -0.51 (-9.59%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$4.80 -0.01 (-0.21%) As of 10/10/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Cognition Therapeutics NASDAQ:CGTX$1.83 -0.12 (-6.15%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.82 -0.02 (-0.82%) As of 10/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Opus Genetics NASDAQ:IRD$1.96 -0.03 (-1.51%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.93 -0.03 (-1.73%) As of 10/10/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Kezar Life Sciences NASDAQ:KZR$4.22 -0.18 (-4.09%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$4.13 -0.09 (-2.11%) As of 10/10/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
